Related Experiment Video

Updated: Jun 28, 2026

Molecular Analysis of Endothelial-mesenchymal Transition Induced by Transforming Growth Factor-β Signaling
07:49

Molecular Analysis of Endothelial-mesenchymal Transition Induced by Transforming Growth Factor-β Signaling

Published on: August 3, 2018

Changes in matrix metalloproteinases and their inhibitors during interferon-beta treatment in multiple sclerosis

Manuel Comabella1, Jordi Río, Carmen Espejo

  • 1Unitat de Neuroimmunologia Clínica, CEM-Cat, Hospital Universitari Vall d'Hebron (HUVH), Barcelona, Spain. mcomabel@ir.vhebron.net

Clinical Immunology (Orlando, Fla.)
|October 24, 2008
PubMed

Insights

Interferon-beta (IFN-b) treatment for multiple sclerosis (MS) impacts matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of metalloproteinase-1 (TIMP-1). An early, sustained increase in TIMP-1 indicates a positive response to IFN-b therapy in MS patients.

Area of Science:

  • Neuroimmunology
  • Biomarker Discovery
  • Pharmacodynamics

Background:

  • Matrix metalloproteinases (MMPs) and tissue inhibitors (TIMPs) are implicated in multiple sclerosis (MS) pathogenesis.
  • MMPs and TIMPs are potential biomarkers for treatment response in MS.

Purpose of the Study:

  • To investigate serum levels of MMPs and TIMPs in relapsing-remitting MS (RRMS) patients treated with interferon-beta (IFN-b).
  • To identify potential biomarkers for predicting response to IFN-b therapy in RRMS patients.

Main Methods:

  • Serum samples from 43 RRMS patients (responders and non-responders to IFN-b) were analyzed.
  • Levels of MMP-2, MMP-7, MMP-9, TIMP-1, and TIMP-2 were measured using ELISA.
  • Neutralizing antibodies to IFN-b were assessed via bioassay.
  • Measurements were taken pre-treatment and at 3, 6, 12, and 24 months post-therapy.

Main Results:

  • Interferon-beta (IFN-b) treatment altered serum levels of MMP-9 and TIMP-1.
  • Responders to IFN-b showed an early and sustained increase in TIMP-1 levels compared to non-responders.
  • MMP-9 levels also changed with IFN-b treatment, though less distinctly than TIMP-1.

Conclusions:

  • An early and sustained increase in TIMP-1 levels may serve as a predictive biomarker for IFN-b treatment response in MS patients.
  • TIMP-1 dynamics during the initial 2 years of therapy offer insights into treatment efficacy.
  • Further research is warranted to validate TIMP-1 as a reliable biomarker for MS therapy.

More Related Videos

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice08:09

Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice

Published on: March 24, 2017

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Role of Matrix Metalloproteases in Degradation of ECM01:23

Role of Matrix Metalloproteases in Degradation of ECM

Matrix metalloproteases (MMPs) are enzymes involved in the hydrolysis of proteins and glycoproteins of the extracellular matrix. MMPs are essential for the migration and proliferation of cells through the dense matrix network, throughout embryonic development, and throughout morphogenesis. The first MMP activity discovered was a collagenase in a tadpole's tail undergoing metamorphosis. The active collagen deposition and modifications lead to the morphogenesis of tadpoles into the adult body.
A...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...